Ferreira DH, et al. - The effects of regular, low-dose, extended-release (ER) morphine for pulmonary arterial hypertension (PAH)-associated chronic breathlessness were evaluated via conducting a randomised, placebo-controlled, double-blind, cross-over study. Researchers performed randomization of participants with PAH-associated chronic breathlessness to i) seven days ER morphine 20mg, ii) seven-day washout and iii) seven days of identically-looking placebo, or vice-versa. On morphine, higher breathlessness “right now” was observed compared with placebo both for morning and evening. All secondary measures of breathlessness were higher with morphine as were nausea and constipation. A phase III study of ER morphine for people with PAH-associated chronic breathlessness was thus not supported.